These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37803345)

  • 1. Cost minimization analysis of a hexavalent vaccine in Argentina.
    Olivera I; Pérez CG; Lazarov L; Lopez E; Oddo C; Dibarboure H
    BMC Health Serv Res; 2023 Oct; 23(1):1067. PubMed ID: 37803345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization.
    Romero M; Góngora DS; Caicedo ML; Benchabane D; Lopez JG
    Value Health Reg Issues; 2021 Dec; 26():150-159. PubMed ID: 34474265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine.
    Olivera I; Grau C; Dibarboure H; Torres JP; Mieres G; Lazarov L; Alvarez FP; Yescas JGL
    BMC Health Serv Res; 2020 Apr; 20(1):295. PubMed ID: 32272920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
    Posuwan N; Wanlapakorn N; Vongpunsawad S; Sintusek P; Leuridan E; Van Damme P; Poovorawan Y
    Vaccine; 2020 Feb; 38(7):1643-1651. PubMed ID: 31948817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
    Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
    Lim FS; Han HH; Jacquet JM; Bock HL
    Ann Acad Med Singap; 2007 Oct; 36(10):801-6. PubMed ID: 17987229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination in children under 1 year with pertussis component in the context of the global initiative for the eradication of poliomyelitis in Argentina: economic analysis].
    Gentile Á; Giglio ND; Castellano V; López JG; Dibarboure H
    Rev Chilena Infectol; 2021 Apr; 38(2):224-231. PubMed ID: 34184714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age.
    Wanlapakorn N; Pruetarat N; Sarawanangkoor N; Phanphanit K; Srimuan D; Thatsanathorn T; Thongmee T; Posuwan N; Poovorawan Y
    Vaccine; 2023 Jun; 41(26):3855-3861. PubMed ID: 37202270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
    Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
    Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP∼T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy.
    Maertens K; Orije MRP; Huoi C; Boisnard F; Lyabis O
    Vaccine; 2023 Jan; 41(3):795-804. PubMed ID: 36528443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.
    Greenberg DP; Doemland M; Bettinger JA; Scheifele DW; Halperin SA; ; Waters V; Kandola K
    Pediatr Infect Dis J; 2009 Jun; 28(6):521-8. PubMed ID: 19436236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.